Thyme Care raised $60 million in series B funding, co-led by Town Hall Ventures and Foresite Capital and with participation from current investors Andreessen Horowitz Bio + Health, AlleyCorp, Casdin Capital, and Frist Cressey Ventures. The capital brings Thyme Care’s total capital raised to over $80 million (The Cancer Letter, Oct. 7, 2022).
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe